Long-term impact of subthalamic stimulation on cognitive function in patients with advanced Parkinson's disease.

Impacto de la estimulación subtalámica a largo plazo sobre la situación cognitiva de los pacientes con enfermedad de Parkinson avanzada.
Calidad de vida Cognitive impairment Deep brain stimulation Depresión Depression Deterioro cognitivo Enfermedad de Parkinson Estimulación cerebral profunda Núcleo subtalámico Parkinson's disease Quality of life Subthalamic nucleus

Journal

Neurologia
ISSN: 2173-5808
Titre abrégé: Neurologia (Engl Ed)
Pays: Spain
ID NLM: 101778590

Informations de publication

Date de publication:
Historique:
received: 24 02 2017
revised: 26 04 2017
accepted: 11 05 2017
pubmed: 18 7 2017
medline: 14 4 2020
entrez: 18 7 2017
Statut: ppublish

Résumé

The aim of this study was to evaluate the effects of deep brain stimulation of the subthalamic nucleus (DBS-SN) on cognitive function in patients with Parkinson's disease (PD) 5 years after surgery. We conducted a prospective study including 50 patients with PD who underwent DBS-SN (62.5% were men; mean age of 62.2±8.2 years; mean progression time of 14.1±6.3 years). All patients were assessed before the procedure and at one year after surgery; 40 patients were further followed up until the 5-year mark. Follow-up assessments included the following neuropsychological tests: Mini-Mental State Examination (MMSE), Mattis Dementia Rating Scale (MDRS), letter-number sequencing of the WAIS-III (WAIS-III-LN), clock-drawing test, Rey auditory verbal learning test (RAVLT), Benton Visual Retention Test (BVRT), Judgment of Line Orientation (JLO) test, FAS Phonemic Verbal Fluency Test, Stroop test, and the Montgomery-Asberg Depression Rating Scale (MADRS). Patients were found to score lower on the MMSE (-0.89%), clock-drawing test (-2.61%), MDRS (-1.72%), and especially phonemic (-13.28%) and sematic verbal fluency tests (-12.40%) at one year after surgery. Delayed recall on the RAVLT worsened one year after the procedure (-10.12%). At 5 years, impairment affected mainly verbal fluency; scores decreased an additional 16.10% and 16.60% in semantic and phonemic verbal fluency, respectively. Moderate decreases were observed in immediate recall (-16.87%), WAIS-III-LN (-16.67%), and JLO test (-11.56%). In our sample, DBS-SN did not result in global cognitive impairment 5 years after surgery. Verbal function was found to be significantly impaired one year after the procedure. Impaired learning and visuospatial function may be attributed to degeneration associated with PD.

Identifiants

pubmed: 28712841
pii: S0213-4853(17)30223-2
doi: 10.1016/j.nrl.2017.05.009
pii:
doi:

Types de publication

Journal Article

Langues

eng spa

Sous-ensembles de citation

IM

Pagination

573-581

Informations de copyright

Copyright © 2017 Sociedad Española de Neurología. Publicado por Elsevier España, S.L.U. All rights reserved.

Auteurs

M Acera (M)

Unidad de Trastornos del Movimiento, Departamento de Neurología, Hospital Universitario de Cruces, Servicio Vasco de Salud, Barakaldo, España; Grupo de Enfermedades Neurodegenerativas, Instituto de Investigación Sanitaria BioCruces, Barakaldo, España.

A Molano (A)

Unidad de Trastornos del Movimiento, Departamento de Neurología, Hospital Universitario de Cruces, Servicio Vasco de Salud, Barakaldo, España; Grupo de Enfermedades Neurodegenerativas, Instituto de Investigación Sanitaria BioCruces, Barakaldo, España.

B Tijero (B)

Unidad de Trastornos del Movimiento, Departamento de Neurología, Hospital Universitario de Cruces, Servicio Vasco de Salud, Barakaldo, España; Grupo de Enfermedades Neurodegenerativas, Instituto de Investigación Sanitaria BioCruces, Barakaldo, España; Departamento de Neurociencias, Universidad del País Vasco, Leioa, España.

G Bilbao (G)

Departamento de Neurociencias, Universidad del País Vasco, Leioa, España; Departamento de Neurocirugía, Hospital Universitario de Cruces, Barakaldo, España.

I Lambarri (I)

Departamento de Neurociencias, Universidad del País Vasco, Leioa, España; Departamento de Neurofisiología, Hospital Universitario de Cruces, Barakaldo, España.

R Villoria (R)

Departamento de Neurociencias, Universidad del País Vasco, Leioa, España; Departamento de Neurorradiología, Hospital Universitario de Cruces, Barakaldo, España.

J Somme (J)

Departamento de Neurología, Hospital Universitario de Álava, Vitoria, España.

E Ruiz de Gopegui (E)

Departamento de Neurocirugía, Hospital Universitario de Cruces, Barakaldo, España.

I Gabilondo (I)

Grupo de Enfermedades Neurodegenerativas, Instituto de Investigación Sanitaria BioCruces, Barakaldo, España.

J C Gomez-Esteban (JC)

Unidad de Trastornos del Movimiento, Departamento de Neurología, Hospital Universitario de Cruces, Servicio Vasco de Salud, Barakaldo, España; Grupo de Enfermedades Neurodegenerativas, Instituto de Investigación Sanitaria BioCruces, Barakaldo, España; Departamento de Neurociencias, Universidad del País Vasco, Leioa, España. Electronic address: juancarlos.gomezesteban@osakidetza.eus.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH